Chemical Industry M&A Counsel in 2026: Sector Outpaces the Practice

A general counsel at a chemicals producer who is choosing chemical industry M&A lawyers is buying into a sector whose deal flow is moving faster than the practice around it. Sartori & Partners data show 373 chemicals deals on record in the 12 months to September 2026, against 279 a year earlier: the sector's count rose 33.7%. Corporate and M&A deal work as a whole went from 10,198 to 11,170 deals over the same two windows, and its count rose 9.5%. Corporate lawyers worked on 33.7% of the sector's deals in the 12 months to October 2026, a close second to capital markets lawyers at 37.6%. The sections below set the sector against the practice on pace, staffing, deal size, firms and hiring, then turn to what it means for the next mandate.

Set side by side, the two changes sit far apart. The chemicals count rose 33.7% on 373 deals against 279; the corporate and M&A count rose 9.5% on 11,170 against 10,198. That puts the sector's pace at 3.5 times the practice's. All dated deals on record, the reference for both, rose 10.6%, from 43,590 to 48,216, so the practice moved close to the market while chemicals pulled clear of both. The sector is small beside the practice: chemicals deals were 0.7% of all dated deals in the 12 months to October 2026, so its change rests on a few hundred matters rather than thousands. A deal in these counts is a matter on record, court and trademark-office filings included, which makes the figures a measure of activity and not of fees. The yearly series below shows the calendar-year counts; 2026 is a partial year, and the earlier years are not a growth record. For a company planning a chemicals transaction, faster deal flow means the teams that do this work are busier than they were a year ago. Ask early about capacity and about who will run the matter day to day.

Staffing tells a company which bench it is really buying. In the 12 months to October 2026, capital markets lawyers worked on 37.6% of chemicals deals (134 deals), corporate and M&A lawyers on 33.7% (120), and banking and finance lawyers on 10.1% (36). The gap between the first two is 3.9 points. These shares overlap, since one deal can carry lawyers from several practices, so they are not a split of the work and are never added together. Against all dated deals, each practice runs higher in this sector. Corporate and M&A lawyers were on 23.3% of deals across the market, which makes their share in chemicals 1.4 times that level. The deal labels point the same way: M&A was the type on 28.9% of chemicals deals against 19.3% of all deals, and capital markets on 36.2% against 25.7%. The practical reading for a buyer is that a chemicals deal often calls for both benches. A company that expects an acquisition to be paid for through a bond or share issue should test the capital markets team as closely as the M&A lead.

Deal size shapes what a mandate costs and which teams can carry it. Where a value was disclosed, the median chemicals deal was $750 million; the median corporate and M&A deal with a disclosed value was $315 million. The sector's middle ticket is therefore 2.4 times the practice's. Values were disclosed on 20.8% of chemicals deals and 17.7% of corporate and M&A deals, so both medians rest on a minority of the work and describe deals announced with a price. The chemicals median also covers capital markets work, a large part of the sector's deals, so it is not a pure M&A figure. Larger tickets narrow the field of firms set up to staff a deal from signing to closing. A company should expect a chemicals transaction to draw on teams used to bigger deals, and should budget the mandate on that basis rather than on a general corporate rate card.

In the Sartori & Partners deal records, the two firm lists below answer different questions, and neither covers the pair itself. The first ranks the firms that advised on the most chemicals deals of any kind in the 12 months to October 2026, capital markets and disputes included. The second ranks the firms with the most corporate and M&A deals across every sector. No list exists for corporate and M&A work in chemicals alone. Counted name by name, three firms appear on both: Latham & Watkins, Kirkland & Ellis and Gibson, Dunn & Crutcher. Latham & Watkins ranks first on the practice list and second on the sector list. The other seven names on each list do not appear on the other. Bands on the chemicals list run from 21-40 deals at the top to 6-10 in tenth place, against 401-700 at the head of the practice list, a reminder of how much smaller the sector is. A firm missing from either list is not a firm without the experience: the lists rank volume on record and nothing more. For a company, the overlap is a short starting point where sector volume and M&A volume meet; for names on one list only, ask for the matching experience directly before a pitch.

Hiring data add a second clock to the picture. Sartori & Partners records show 2,933 lateral moves of corporate and M&A lawyers between firms in the 12 months to September 2026, against 2,532 a year earlier, so the count rose 15.8%. These are moves of lawyers, not deals, and their timing next to the sector's deal growth is a parallel, not a cause. Lawyers whose own focus is chemicals moved at a steadier rate: 61 moves against 59, a count that held flat (+3.4%). Partners made up 61.0% of the chemicals-focus moves in the 12 months to October 2026, against 29.9% of corporate and M&A moves, and 47.5% of the chemicals-focus moves were recorded under litigation and disputes. The message for a company is about supply. The corporate bench is turning over faster, so the partner who pitches today may sit at another firm within a year. The pool of lawyers with a chemicals focus is small and steady, so a team with that focus is hard to replace once a deal is under way. Ask who on the team carries the sector focus, and how long the group has worked together.

Four points follow from the figures. First, book early: the sector's deal count rose 33.7% in a year when the practice's count rose 9.5%, so the teams that do this work carry more of it. Second, staff both benches: capital markets lawyers were on 37.6% of chemicals deals and corporate lawyers on 33.7%, so a transaction with a financing leg needs the two teams tested together, not one after the other. Third, budget for size: the median disclosed chemicals deal was 2.4 times the practice's median, and the fee estimate should reflect a larger, more document-heavy deal. Fourth, treat the two firm lists as volume on record and check sector experience firm by firm, partner by partner. A shortlist that starts with the firms on both lists and adds a firm with a named chemicals-focus partner covers the deal side and the sector side at once. Given how steady the chemicals-focus moves have been, that partner is the scarcer resource, and the one to secure first.